Invitrogen™ N-CAM1 Human ELISA Kit

Beschreibung

The Human Neuronal Cell Adhesion Molecule-1(Hu N-CAM1) ELISA quantitates Hu N-CAM1 in human serum, plasma, or cell culture medium. The assay will exclusively recognize both natural and recombinant Hu N-CAM1. Principle of the method The Human N-CAM1 solid-phase sandwich ELISA (enzyme-linked immunosorbent assay) is designed to measure the amount of the target bound between a matched antibody pair. A target-specific antibody has been pre-coated in the wells of the supplied microplate. Samples, standards, or controls are then added into these wells and bind to the immobilized (capture) antibody. The sandwich is formed by the addition of the second (detector) antibody, a substrate solution is added that reacts with the enzyme-antibody-target complex to produce measurable signal. The intensity of this signal is directly proportional to the concentration of target present in the original specimen. Rigorous validation Each manufactured lot of this ELISA kit is quality tested for criteria such as sensitivity, specificity, precision, and lot-to-lot consistency. See manual for more information on validation.

CD56 (NCAM, neural cell adhesion molecule) is a transmembrane glycoprotein of the immunoglobulin family that serves as an adhesive molecule and is ubiquitously expressed in the nervous system in isoforms ranging from 120-180 kDa. CD56 is found on T cells and NK cells, and is involved in cell migration, axonal growth, pathfinding and synaptic plasticity. Polysialic modification results in reduction of CD56-mediated cell adhesion. Through its extracellular region, CD56 mediates homophilic and heterophilic interactions by binding extracellular matrix components such as laminin and integrins. CD56 is expressed on most neuroectodermal derived cell lines, tissues and neoplasms such as retinoblastoma, medulloblastoma, astrocytomas and neuroblastoma. Further, CD56 is a widely used neuroendocrine marker with a high sensitivity for neuroendocrine tumors and ovarian granulosa cell tumors. Diseases associated with CD56 dysfunction include rabies and blastic plasmacytoid dendritic cell neoplasms.